AVTX
Avalo Therapeutics, Inc.
There isn't enough reported data to score AVTX yet.
AVTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
AVTX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
AVTX PE Valuation
AVTX has no meaningful PE right now: it lost money over the past year.
AVTX Forward outlook
There aren't enough analyst estimates for AVTX to show an outlook.
AVTX Earnings Per Share
AVTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $59K | -69% |
| Q4 2024 | $192K | -66% |
| Q3 2024 | $249K | +5.5% |
| Q4 2023 | $571K | -36% |
| Q3 2023 | $236K | -98% |
| Q2 2023 | $643K | -38% |
| Q1 2023 | $475K | -60% |
| Q4 2022 | $896K | +309% |
AVTX's revenue has slid since its 2022 peak: $59,000 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -33461% | -26528 points |
| Q4 2024 | -6933% | -5592 points |
| Q3 2024 | -5165% | -3576 points |
| Q4 2023 | -1341% | -353 points |
| Q3 2023 | -1589% | -1616 points |
| Q2 2023 | -1112% | +33 points |
| Q1 2023 | -1851% | -73 points |
| Q4 2022 | -988% | +7214 points |
AVTX's operating margin was −33461% last quarter, down 31872 points from the same quarter a year ago, near the bottom of its range since 2020.
AVTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$11.5M | +$4.8M |
| Q2 2026 | -$20M | -$8.6M |
| Q1 2026 | -$17.7M | -$8.2M |
| Q4 2025 | -$14.2M | +$798K |
| Q3 2025 | -$16.4M | -$4.8M |
| Q2 2025 | -$11.4M | +$4.9M |
| Q1 2025 | -$9.5M | -$3.3M |
| Q4 2024 | -$15M | -$12.3M |
AVTX has burned cash in almost every quarter: −$63M over the past year, against −$52M the year before.
AVTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +11.5M shares |
| 1 year | +408% | +44.2M shares |
AVTX has 55M diluted shares, up 408% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
AVTX Net Leverage
AVTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
AVTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 5.1 | Oversold |
AVTX's weekly RSI is 31 (neutral) and its Stochastic is 5 (oversold).
AVTX PE vs Healthcare Sector
AVTX has no meaningful PE right now: it lost money over the past year.
AVTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.5 | 27% below |
| 20 week MA | $15.4 | 50% below |
| 50 week MA | $15.7 | 51% below |
| 100 week MA | $12.2 | 37% below |
| 200 week MA | $96.8 | 92% below |
AVTX is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
AVTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14,774.4 | $7,920.0 | -46% |
| 2021 | $7,920.0 | $5,356.8 | -32% |
| 2022 | $5,356.8 | $1,202.4 | -78% |
| 2023 | $1,202.4 | $9.10 | -99% |
| 2024 | $9.10 | $8.33 | -8.5% |
| 2025 | $8.33 | $18.4 | +121% |
| 2026 YTD | $18.4 | $7.70 | -58% |
AVTX's yearly returns have swung widely, from +121% in 2025 to −99% in 2023. It's down 58% so far in 2026.